Answers are grounded in this paper and cite their sources.
Rheumatology 2017;56:1056–1059. doi:10.1093/rheumatology/kex150 Rheumatology 2017;56:e1–e20. doi:10.1093/rheumatology/kex156 The Publishers would like to apologize for an error in the above papers. The following sentence has been adapted from ‘An NSAID at maximum dose and colchicine in doses of 500 μg bd–qds is the drugs of choice when there are no contraindications’ to ‘An NSAID at maximum dose or colchicine in doses of 500 μg bd-qds is the drug of choice when there are no contraindications.’ This has been corrected online and in print.
No takes yet. Share an insight, caveat, or question.
Hui et al. (2017) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: